Achromatopsia Pipeline, Clinical Trials Assessment 2023 (Updated)| Companies - MeiraGTx, Janssen Pharmaceuticals, Applied Genetic Technologies Corporation, and others

DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Achromatopsia Pipeline, providing valuable insights into emerging therapies, companies, and future outlooks.

DelveInsight's, "Achromatopsia Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Achromatopsia pipeline landscape. It covers the Achromatopsia pipeline drug profiles, including Achromatopsia clinical trials and nonclinical stage products. It also covers the Achromatopsia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Achromatopsia Pipeline treatment landscape of the report, click here @ Achromatopsia Pipeline Outlook- https://www.delveinsight.com/report-store/achromatopsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Achromatopsia Pipeline Report
• DelveInsight's Achromatopsia Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Achromatopsia.
• The leading Achromatopsia Companies include MeiraGTx, Janssen Pharmaceuticals, Applied Genetic Technologies Corporation, and others
• Promising Achromatopsia Pipeline Therapies include AAV-CNGA3, AGTC-401, and others
• AGTC-401 and AGTC-402, being developed by Applied Genetic Technologies Corporation (AGTC) are two separate AAV gene therapy product candidates of AGTC for the two most prevalent forms of ACHM, caused by either a genetic mutation in the CNGB3 or CNGA3 genes. AGTC conducted two separate Phase I/II (NCT02935517, NCT02599922) clinical trials to evaluate the safety and efficacy of AAV gene therapy product candidates in adults and children with ACHM caused by CNGB3 or CNGA3 mutations. Goals of the study are to look at the safety and effectiveness of an experimental gene therapy to treat achromatopsia.
• AAV CNGA3 and AAV-CNGB3 are gene therapies, being developed by Janssen Pharmaceuticals (a subsidiary of Johnson and Johnson) in collaboration with MeiraGTx, designed to restore cone function. These therapies are non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector. AAV-CNGB3 and AAV-CNGA3 are delivered via subretinal injection to the area of the eye where most of the cones in the retina are located.

For further information, refer to the detailed Achromatopsia Unmet Needs, Achromatopsia Market Drivers, and Achromatopsia Market Barriers, click here for Achromatopsia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/achromatopsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Achromatopsia Overview
Achromatopsia is characterized by reduced visual acuity, pendular nystagmus, increased sensitivity to light (photophobia), a small central scotoma, eccentric fixation, and reduced or complete loss of color discrimination. All individuals with achromatopsia (achromats) have impaired color discrimination along all three axes of color vision corresponding to the three cone classes: the protan or long-wavelength-sensitive cone axis (red), the deutan or middle-wavelength-sensitive cone axis (green), and the tritan or short-wavelength-sensitive cone axis (blue).

Request a sample and discover the recent advances in Achromatopsia Ongoing Clinical Trial Analysis and Medications, click here @ Achromatopsia Treatment Landscape- https://www.delveinsight.com/sample-request/achromatopsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Achromatopsia Emerging Drugs
• AAV-CNGA3: Janssen Pharmaceutical
AAV-CNGA3, gene therapy candidate designed to restore cone function, are delivered via subretinal injection to the area of the eye where most of the cones in the retina are located. Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases. Under the terms of the agreement, MeiraGTx to grant Janssen an exclusive worldwide license to certain clinical assets in MeiraGTx's inherited retinal disease portfolio. The companies have also formed a research collaboration to develop a pipeline of products addressing novel gene targets, giving Janssen the exclusive option to license new treatments for other inherited retinal diseases.

Dive deep into rich insights for drugs for Achromatopsia Market Drivers and Achromatopsia Market Barriers, click here @ Achromatopsia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/achromatopsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Achromatopsia Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Achromatopsia. The companies which have their Achromatopsia drug candidates in the most advanced stage, i.e. Phase I/II include, Janssen Pharmaceutical.

Scope of the Achromatopsia Pipeline Report
• Coverage- Global
• Achromatopsia Companies- MeiraGTx, Janssen Pharmaceuticals, Applied Genetic Technologies Corporation, and others
• Achromatopsia Pipeline Therapies- AAV-CNGA3, AGTC-401, and others
• Achromatopsia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Achromatopsia Mergers and acquisitions, Achromatopsia Licensing Activities @ Achromatopsia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/achromatopsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Achromatopsia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Achromatopsia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. AAV-CNGA3: Janssen Pharmaceutical
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Achromatopsia Key Companies
24. Achromatopsia Key Products
25. Achromatopsia -Unmet Needs
26. Achromatopsia -Market Drivers and Barriers
27. Achromatopsia -Future Perspectives and Conclusion
28. Achromatopsia Analyst Views
29. Achromatopsia Key Companies
30. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.